ProCE Banner Activity

CME

Cancer Conversations: BTK Inhibitor Therapies for CLL/SLL and MCL in 2022

Conference Coverage
Multimedia

Watch this on-demand webcast capturing a dynamic workshop in which 3 experts discuss best practices and future directions in the use of BTK inhibitors for chronic lymphocytic leukemia and mantle cell lymphoma.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 22, 2022

Expiration: November 21, 2023

No longer available for credit.

Share

Faculty

Matthew S. Davids

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Jeffrey P. DONOTUSESharman

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Anthony Mato

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Target Audience

This educational program is intended for hematologists, medical oncologists, and other healthcare professionals who treat patients with CLL/SLL and MCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate emerging BTK inhibitor data considering the potential impact of safety and efficacy results on clinical practice
  • Plan BTKi-based therapeutic strategies for patients with R/R CLL/SLL or R/R MCL, taking into consideration global indications and recent practice-changing clinical trial results
  • Select and sequence therapy for patients with resistance to or intolerance of first-line BTKi-based therapy to optimize clinical outcomes
  • Identify patients who may be eligible for ongoing clinical trials evaluating currently available and emerging BTKis and BTKi-based combinations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Matthew S. Davids, MD, MMSc: researcher: AstraZeneca, Genentech, MEI Pharma, Novartis, Pharmacyclics, Surface Oncology, TG Therapeutics, Verastem; consultant: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck, Ono Pharmaceuticals, Research to Practice, Takeda, TG Therapeutics, Verastem, Zentalis.

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

Jeff Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Anthony Mato, MD, MSCE: researcher: AbbVie, Acerta/AstraZeneca, Adaptive, DTRM BioPharma, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Regeneron, Sunesis, TG Therapeutics; consultant: AbbVie, Acerta/AstraZeneca, Adaptive, AstraZeneca, Celgene, DTRM BioPharma, Genentech, Genmab, Johnson & Johnson, Loxo Oncology, Nurix, Pharmacyclics, Sunesis, TG Therapeutics, Verastem.

Planner/Manager Text

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 22, 2022, through November 21, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners in selecting the optimal BTKi-based regimens for patients with relapsed/refractory CLL/SLL and relapsed/refractory MCL.